Illumina, Inc. $ILMN Stock: Focus Advisor Solutions LLC Boosts Holdings

Focus Advisor Solutions LLC boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 68.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,224 shares of the life sciences company’s stock after acquiring an additional 10,278 shares during the quarter. Focus Advisor Solutions LLC’s holdings in Illumina were worth $6,904,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Illumina in the second quarter valued at about $3,374,423,000. Primecap Management Co. CA acquired a new position in shares of Illumina in the second quarter worth approximately $617,981,000. Ninety One UK Ltd boosted its holdings in Illumina by 37,920.0% in the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company’s stock valued at $372,198,000 after acquiring an additional 1,356,397 shares during the last quarter. Jupiter Topco LLC acquired a new stake in Illumina during the 2nd quarter valued at approximately $358,652,000. Finally, Wellington Management Group LLP increased its position in Illumina by 190.1% during the 2nd quarter. Wellington Management Group LLP now owns 1,812,928 shares of the life sciences company’s stock valued at $318,767,000 after purchasing an additional 1,188,004 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ILMN. Leerink Partners boosted their price target on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $135.00 to $260.00 in a research note on Wednesday, September 9th. TD Cowen boosted their target price on shares of Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Citigroup upped their price target on shares of Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a research report on Monday, November 2nd. Finally, Jefferies Financial Group set a $235.00 price target on Illumina and gave the stock a “hold” rating in a report on Monday. Nine equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $243.72.

Check Out Our Latest Stock Analysis on Illumina

More Illumina News

Here’s some of the latest news about ILMN:

  • Positive Sentiment: Illumina’s BioInsight AI Lab won the 2026 Virtual Cell Challenge using its Billion Cell Atlas and CellularAI algorithm. The result showcases the company’s AI and genomic-data capabilities, though the announcement does not specify near-term revenue impact. Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
  • Positive Sentiment: A proposed federal bill would require Medicaid coverage for whole-genome and whole-exome sequencing for certain children. If enacted, broader coverage could support more genetic testing and demand for Illumina’s sequencing systems; the bill is not yet law. Genomic Answers for Children’s Health Act of 2026
  • Neutral Sentiment: Recent coverage attributes Illumina’s strong year-over-year performance to clinical sequencing demand, NovaSeq X adoption, and expansion into multiomics and AI. These longer-term drivers may support investor sentiment, but are not a new quarterly update. What’s Fueling Illumina’s Rally?

Illumina Price Performance

ILMN stock opened at $200.65 on Friday. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The business has a 50-day simple moving average of $248.54 and a two-hundred day simple moving average of $180.77. The company has a market capitalization of $30.34 billion, a P/E ratio of 40.00, a price-to-earnings-growth ratio of 2.85 and a beta of 1.46.

Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the firm posted $1.34 EPS. Illumina’s quarterly revenue was up 4.2% compared to the same quarter last year. Research analysts expect that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, Director Keith Meister sold 231,433 shares of Illumina stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $238.52, for a total transaction of $55,201,399.16. Following the sale, the director directly owned 538,917 shares in the company, valued at approximately $128,542,482.84. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 1,201,292 shares of company stock valued at $270,151,290. 2.90% of the stock is owned by insiders.

About Illumina

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Featured Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.